Zentalis Pharmaceuticals Inc expected to post a loss of 53 cents a share - Earnings Preview

Zentalis Pharmaceuticals

05/08/2025 15:27

Zentalis Pharmaceuticals Inc ZNTL.OQ ZNTL.O is expected to  show no change in quarterly revenue when it reports  results on August 7 (estimated) for the period ending June 30 2025

​LSEG's mean analyst estimate for Zentalis Pharmaceuticals Inc is for a loss of 53 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," 5 "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Zentalis Pharmaceuticals Inc is $6.00, about 76.8% above its last closing price of $1.39

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATEÂŪ
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2025
-0.65
-0.64
-0.56
Beat
12.2
Dec. 31 2025
-0.62
-0.71
-0.62
Beat
12.2
Sep. 30 2024
-0.88
-0.91
-0.56
Beat
38.5​
Jun. 30 2024
-0.87
-0.84
-1.24
Missed
-47.5
​​Mar. 31 2024
-0.76
-0.77
0.14
Beat
118.3
Dec. 31 2023
-0.94
-0.92
-0.93
Missed
-1.5​
Sep. 30 2023
-0.91
-0.91
-0.79
Beat
13.3
Jun. 30 2023
-1.02
-1.04
-1.85
Missed
-78.3

This summary was machine generated August 5 at 14:27 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)